logo

For the Inventor, By the Inventor

Ljubljana, Slovenia

Lek Pharmaceuticals D.d.


USPTO Granted Patents = 107

% Expired Patents = 74.8



Forward Citations = 204

Loading Chart...
Loading Chart...

145 inventors (with patents filed for the assignee):

goldMedal Zdenko Casar (15 out of 15 patents)

silverMedal Anton Copar (10 out of 14 patents)

bronzeMedal Zlatko Pflaum (10 out of 11 patents)

4.  Rok Grahek (8 out of 9 patents)

5.  Janez Kerc (8 out of 9 patents)

6.  Igor Legen (7 out of 8 patents)

7.  Lovro Selic (6 out of 6 patents)

8.  Andrej Bastarda (6 out of 7 patents)

9.  Mateja Salobir (5 out of 5 patents)

10.  Damjan Sterk (5 out of 6 patents)

11.  Peter Mrak (5 out of 5 patents)

12.  Gregor Kopitar (5 out of 5 patents)

13.  Marko Zlicar (5 out of 5 patents)

14.  Viktor Menart (5 out of 5 patents)

15.  Renata Toplak Casar (5 out of 5 patents)


Core Competencies:
Pharmaceutical Composition
Glycoproteins
Protein Expression
Dolutegravir
Cabotegravir
Sitagliptin
Statins
Erythropoietin
Self-Microemulsifying
Angiotensin II Antagonists
Crystalline Forms
Cell Line Development

107 patents:

1. 10913985 - Predicting productivity in early cell line development (2021-02-09),
2. 10913984 - Predicting genetically stable recombinant protein production in early cell line development (2021-02-09),
3. 10357431 - Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient (2019-07-23),
4. 10335394 - Processes for preparing dolutegravir and cabotegravir and analogues thereof (2019-07-02),
5. 10323056 - Crystalline hydrates of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene (2019-06-18),
6. 10196601 - Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides (2019-02-05),
7. 9907757 - Coated particles and pharmaceutical dosage forms (2018-03-06),
8. 9732053 - 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form (2017-08-15),
9. 9707178 - Pharmaceutical composition (2017-07-18),
10. 9637769 - Reduction of formation of amidated amino acids in cell lines for protein expression (2017-05-02),
11. 9622976 - Pharmaceutical composition (2017-04-18),
12. 9562082 - Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content (2017-02-07),
13. 9512097 - Process for the preparation of 3-aroyl-5-aminobenzofuran derivatives (2016-12-06),
14. 9499857 - Selection of triploid CHO cells and cell lines expressing recombinant polypeptides as high producers (2016-11-22),
15. 9493409 - Process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine (2016-11-15),
Company Overview
Lek Pharmaceuticals D.d., headquartered in Ljubljana, Slovenia, is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of a wide range of pharmaceutical compositions. The company focuses on advanced therapeutic areas, including glycoproteins and protein expression technologies, contributing significantly to treatments involving dolutegravir, cabotegravir, sitagliptin, statins, and erythropoietin. Lek is committed to innovation and quality in its pharmaceutical offerings, serving both local and international markets.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

107 Patents

#1 in Ljubljana

#1 in Slovenia

#7,336 in the World

Ljubljana, SI
Ljubljana, Slovenia

Lek Pharmaceuticals D.d.

Forward Citations = 204

145 inventors:

goldMedal Zdenko Casar (15 out of 15 patents)

silverMedal Anton Copar (10 out of 14 patents)

bronzeMedal Zlatko Pflaum (10 out of 11 patents)

4.  Rok Grahek (8 out of 9 patents)

5.  Janez Kerc (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lek Pharmaceuticals D.d.. Retrieved from https://idiyas.com/company/lek-pharmaceuticals-d-d

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…